Role of Thrombin-Activatable Fibrinolysis Inhibitor in Allergic Bronchial Asthma
- 323 Downloads
Bronchial asthma is an inflammatory disease of the airways. Thrombin-activatable fibrinolysis inhibitor (TAFI) is a carboxypeptidase that besides inhibiting fibrinolysis, also regulates inflammatory processes. The only validated substrate known for TAFI is fibrin. In the present study we evaluated the role of TAFI in bronchial asthma by comparing the development of allergic bronchial asthma between wild-type (WT) and TAFI-deficient mice (KO).
Asthmatic inflammation was induced by sensitization and challenge with ovalbumin in WT (WT/OVA) and TAFI KO (KO/OVA) mice. WT mice (WT/SAL) and TAFI KO (KO/SAL) were used as controls. Cytokines, markers of inflammation, and coagulation were measured in bronchoalveolar lavage fluid (BALF).
Airway hyperresponsiveness was worse in KO/OVA mice than in WT/OVA mice or control mice. Markers of lung injury were significantly increased in BALF from KO/OVA mice compared to WT/OVA mice. Airway hyperresponsiveness and the BALF concentrations of IL-5 and osteopontin were significantly increased in KO/OVA mice compared to WT/OVA mice. Treatment of WT/OVA and KO/OVA mice with a C5a receptor antagonist significantly decreased hyperresponsiveness along with the BALF concentrations of total protein and C5a compared to untreated asthmatic mice.
The results of this study suggest that TAFI plays a protective role in the pathogenesis of allergic inflammation probably by inhibiting the complement system.
KeywordsBronchial asthma Coagulation Fibrinolysis Inflammation Allergy
The present investigation was supported by Grants-in-Aid (Nos. 18590846 and 17590788) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. JM was supported by JSPS scholarship L8020.
Conflict of interest
- 12.Bautsch W, Hoymann HG, Zhang Q, Meier-Wiedenbach I, Raschke U, Ames RS, Sohns B, Flemme N, Vilsendorf AMZ, Grove M, Klos A, Kohl J (2000) Cutting edge: guinea pigs with a natural C3a-receptor defect exhibit decreased bronchoconstriction in allergic airway disease: evidence for an involvement of the C3a anaphylatoxin in the pathogenesis of asthma. J Immunol 165:5401–5405PubMedGoogle Scholar
- 17.Yuda H, Adachi Y, Taguchi O, Gabazza EC, Hataji O, Fujimoto H, Tamaki S, Nishikubo K, Fukudome K, D’Alessandro-Gabazza CN, Maruyama J, Izumizaki M, Iwase M, Homma I, Inoue R, Kamada H, Hayashi T, Kasper M, Lambrecht BN, Barnes PJ, Suzuki K (2004) Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice. Blood 103:2196–2204PubMedCrossRefGoogle Scholar
- 27.Shimizu S, Shimizu T, Morser J, Kobayashi T, Yamaguchi A, Qin L, Toda M, D’Alessandro-Gabazza C, Maruyama T, Takagi T, Yano Y, Sumida Y, Hayashi T, Takei Y, Taguchi O, Suzuki K, Gabazza EC (2008) Role of the coagulation system in allergic inflammation in the upper airways. Clin Immunol 129:365–371PubMedCrossRefGoogle Scholar
- 28.Cho SH, Ryu CH, Oh CK (2004) Plasminogen activator inhibitor-1 in the pathogenesis of asthma. Exp Biol Med (Maywood) 229:138–146Google Scholar
- 31.Nemeth K, Keane-Myers A, Brown JM, Metcalfe DD, Gorham JD, Bundoc VG, Hodges MG, Jelinek I, Madala S, Karpati S, Mezey E (2010) Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci USA 107:5652–5657PubMedCrossRefGoogle Scholar